anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lanabecestat
Trial phase: Phase 2 | Phase 3
SMILES: CC#Cc1cncc(-c2ccc3c(c2)[C@@]2(N=C(C)C(N)=N2)[C@]2(CC[C@H](OC)CC2)C3)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 735
Group description: Participants received lanabecestat 50 mg film-coated oral tablets once daily.
Eligibility criteria:
Inclusion Criteria:

Gradual and progressive change in the participant's memory function over more than 6 months, reported by participant and study partner
Mini-Mental State Examination score of 20-30 inclusive at screening
Objective impairment in memory as evaluated by memory test performed at screening
For a diagnosis of mild Alzheimer's Disease (AD), participant meets the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria for probable AD
For a diagnosis of MCI due to AD, participant meets NIA-AA criteria for MCI due to AD

Exclusion Criteria:

Significant neurological disease affecting the central nervous system, other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson´s disease, or epilepsy or recurrent seizures
History of clinically evident stroke, or multiple strokes based on history or imaging results
History of clinically important carotid or vertebrobasilar stenosis or plaque
History of multiple concussions with sustained cognitive complaints or objective change in neuropsychological function in the last 5 years
Participants with a current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of Major Depressive Disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study
History of alcohol or drug abuse or dependence (except nicotine dependence) within 2 years before the screening
Within 1 year before the screening or between screening and baseline, any of the following: myocardial infarction; moderate or severe congestive heart failure, New York Heart Association class III or IV; hospitalization for, or symptom of, unstable angina; syncope due to orthostatic hypotension or unexplained syncope; known significant structural heart disease (eg, significant valvular disease, hypertrophic cardiomyopathy), or hospitalization for arrhythmia
Congenital QT prolongation
History of cancer within the last 5 years, with the exception of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, non-progressive prostate cancer or other cancers with low-risk of recurrence or spread
Current serious or unstable clinically important systemic illness that, in the judgment of the investigator, is likely to affect cognitive assessment, deteriorate, or affect the participant's safety or ability to complete the study, including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, or hematologic disorders
Intervention: Histidine
Trial phase: Phase 4
SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg, chlorpheniramine 2mg and dextromethorphan 15mg).
Eligibility criteria:
Inclusion Criteria:

Aged at least 18 years and less than 65 years
Good general and mental health in the opinion of the investigator

Participants diagnosed with a common cold or flu and must have the following symptoms of at least "moderate" in intensity (≥ 2) at the screening visit (baseline), with a minimum total symptom score of 6:

(i) At least one of pain symptoms: sore throat, headache, or extremities pain (ii) Mandatory: Nasal congestion (iii) At least one of catarrh symptoms: runny nose or sneezing

Onset of first symptoms of cold must have occurred within 48 hours of screening.

Exclusion Criteria:

Pregnant or breast feeding women
History of seasonal or perennial allergic rhinitis or acute, sub-chronic, or chronic cough due to any condition other than a common cold or flu, as determined by the investigator
Concurrent illness or medical history that is contraindicated or cautioned about in the drug label
Anatomical factors causing nasal congestion
Fever with body temperature >38.5°C at baseline
Have used any medication or herbal remedies to treat cold prior to screening (antibiotics in the last 7 days, antihistamines in the last 72 hours, analgesics or antipyretics in the last 24 hours, decongestant in the last 12 hours, antitussive, medicated lozenge or throat spray in the last 8 hours)
Any medication that has potential drug-drug interactions with study medications
Known or suspected intolerance or hypersensitivity to the study materials
Have a positive drug urine test or recent history (within the last 2 years) of alcohol or other substance abuse
Intervention: Resveratrol
Trial phase: Not Applicable
SMILES: Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
Eligibility criteria:
Inclusion Criteria:

Ankle-brachial index (ABI) < 0.90 at baseline screening (at visit), or, medical evidence of prior lower extremity revascularization if ABI ≥ 0.90.
65 or older

Exclusion Criteria:

Above/below-knee amputation, critical limb ischemia, wheelchair-bound, or require the use of a walker or cane
Other symptom(s) limiting walking ability, other than PAD
Underwent/experienced lower extremity revascularization, a cardiovascular event, or coronary artery bypass surgery within 3 months of screening. Underwent major orthopedic surgery within 6 months of screening. Planning to have revascularization or major elective surgery within the next 6 months.
Major medical illness including renal disease that requires dialysis or lung disease that requires oxygen
Score of < 23 on Mini-Mental Status Examination at screening or major psychiatric illness
Currently participating in a separate clinical trial
Significant renal or liver dysfunction at baseline
Does not successfully complete the study run-in period
Has an extreme baseline 6 minute walk value (< 500 ft or > 1,600 feet )
Treated for cancer during the last 2 years (unless prognosis is excellent)
Severe hearing impairment or other communication difficulties (e.g. non-English speaking) or legally blind
Diagnosis of Parkinson's disease
Unable to return to medical center at required visit frequency
Otherwise poorly suited to intervention (at the discretion of the PI)
Intervention: Resveratrol
Trial phase: Not Applicable
SMILES: Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
Eligibility criteria:
Inclusion Criteria:

Ankle-brachial index (ABI) < 0.90 at baseline screening (at visit), or, medical evidence of prior lower extremity revascularization if ABI ≥ 0.90.
65 or older

Exclusion Criteria:

Above/below-knee amputation, critical limb ischemia, wheelchair-bound, or require the use of a walker or cane
Other symptom(s) limiting walking ability, other than PAD
Underwent/experienced lower extremity revascularization, a cardiovascular event, or coronary artery bypass surgery within 3 months of screening. Underwent major orthopedic surgery within 6 months of screening. Planning to have revascularization or major elective surgery within the next 6 months.
Major medical illness including renal disease that requires dialysis or lung disease that requires oxygen
Score of < 23 on Mini-Mental Status Examination at screening or major psychiatric illness
Currently participating in a separate clinical trial
Significant renal or liver dysfunction at baseline
Does not successfully complete the study run-in period
Has an extreme baseline 6 minute walk value (< 500 ft or > 1,600 feet )
Treated for cancer during the last 2 years (unless prognosis is excellent)
Severe hearing impairment or other communication difficulties (e.g. non-English speaking) or legally blind
Diagnosis of Parkinson's disease
Unable to return to medical center at required visit frequency
Otherwise poorly suited to intervention (at the discretion of the PI)
Intervention: SODIUM CHLORIDE
Trial phase: Phase 1 | Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Injection of normal saline into cleft lip at time of surgical repair.

Normal Saline Injection: Injection of normal saline into cleft lip at time of surgical repair. Saline will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
Eligibility criteria:
Inclusion Criteria:

complete unilateral cleft lip with or without cleft palate
planned for a primary cleft lip repair

Exclusion Criteria:

-bilateral cleft lip
Intervention: Ciprofloxacin
Trial phase: Not Applicable
ATC code: J01MA02 | J01RA10 | J01RA11 | J01RA12 | S01AE03 | S02AA15 | S03AA07
SMILES: O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 175
Group description: Antibiotic

Ciprofloxacin
Eligibility criteria:
Inclusion Criteria:

Subjects will include patients undergoing radical prostatectomy for prostate cancer. Subjects will be randomized into control or treatment group.

Exclusion Criteria:

Subjects with a history of adverse reaction to ciprofloxacin, or any other quinolone will be excluded. Subjects being treated with tizanidine or with a history of myasthenia gravis will be excluded. In addition, we will exclude patients with major immediate post-operative complications after prostatectomy including significant post-operative bleeding with known pelvic hematoma and known urine leak.
Intervention: Betamethasone Sodium Phosphate
Trial phase: Phase 3
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.

Corticosteroid: Corticosteroid
Eligibility criteria:
Inclusion Criteria:

Patients at least 18 years old.
Patients with baker's cyst who also present with at least one of the following: swelling, local pain or discomfort, limited range of motion or any other symptom directly caused by the baker's cyst.

Exclusion Criteria:

Patients younger than 18 years old
Local or Systemic active infection
Active cancer treatment
Immunodeficiency
Diabetes
Hypersensitivity or allergy to Corticosteroid or Lidocaine
Intervention: Midazolam
Trial phase: Phase 3
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 75
Group description: In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication

Midazolam: oral midazolam 0.5mg/kg upto maximum dose of 15mg
Eligibility criteria:
Inclusion Criteria:

Children older than 5yrs and weighing more than 20kg , who are scheduled for ambulatory dental rehabilitation at Batson operating rooms.
ASA classification 1 or 2

Exclusion Criteria

Known allergy to midazolam, dexmedetomidine,morphine, fentanyl, sevoflurane and propofol.
uncorrected congenital heart disease or history of cardiac arrhythmia,
children at risk for airway obstruction (OSA or cranio facial syndrome),
pregnant minors
Intervention: Racivir
Trial phase: Not Applicable
ATC code: J05AF09 | J05AR03 | J05AR06 | J05AR08 | J05AR09 | J05AR17 | J05AR18 | J05AR19 | J05AR20 | J05AR22
SMILES: Nc1nc(=O)n(C2CSC(CO)O2)cc1F
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Genvoya Arm is for participants already taking Genvoya at the time of study entry. Participants taking Genvoya at the time of study entry will continue Genvoya for the second PK.

Genvoya: To be administered orally, once daily with food.
Eligibility criteria:
Inclusion Criteria:

Adult men or women aged 18-60 years. Able and willing to provide informed consent.
Presence of HIV-1 infection as documented by a licensed ELISA test kit and confirmed by Western blot or HIV RNA.
Track A (Currently taking E/C/F/TDF or E/C/F/TAF): Taking E/C/F/TDF or E/C/F/TAF for at least 3 months prior to screening and undetectable plasma HIV-1 RNA (≤ 40 copies/mL)
Track B (Currently not taking ART): Off ART for at least 3 months. Prior exposure to TDF and FTC will be allowed but subjects must not have primary genotypic drug resistance mutations to elvitegravir, tenofovir, or emtricitabine (see Exclusion Criteria)
Plasma HIV-1 RNA ≥ 5,000c/mL and CD4+ T-cell count ≥200cells/mm3.

Exclusion Criteria:

Track B: Presence of primary drug resistance mutations for EVG, tenofovir, or emtricitabine.
Use of drugs of abuse or alcohol which would interfere with adherence or completion of this study. While on-study, subjects will be instructed not to consume alcohol for 48 hours prior to pharmacokinetic sampling days.
Pregnancy or breast-feeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to study entry and day of entry.
Chronic, severe, or other medical conditions that, in the opinion of the investigator, would interfere with the subjects ability to participate in the protocol.
Use of prohibited protocol-specified drugs, prescription or over-the-counter, within 14 days prior to study entry.
Bleeding abnormality or other contraindication to lumbar puncture.
Moderate or severe cognitive impairment by history or based on Montreal Cognitive Assessment.
Hepatitis B surface antigen (HBsAg) positive (Positive anti-HBs antibody and negative HBsAg results are acceptable)
Hepatitis C antibody (HCV Ab) positive

Laboratory parameters documented within 21 days prior to study entry that would increase the risk for adverse events:

Hemoglobin < 12.5 g/dL for men; < 11.5 g/dL for women;
Platelet count < 100,000 platelets/mm3;
AST (SGOT) or ALT (SGPT) > 1.5 x the upper limit of normal (ULN);
Estimated GFR<70 ml/min
Weight less than 50 kg
Intervention: OXYTOCIN
Trial phase: Phase 2
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: Intranasal oxytocin doses 2-3 times/day for 12 weeks

Intranasal Oxytocin: 10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Meeting criteria for DSM-IV-TR alcohol dependence.
Consumption of at least 35 standard drinks/week for men or 28 standard drinks/week for women for at least 4 consecutive weeks prior to enrollment into the study.
Women who are able to conceive children and who are sexually active must be on an effective form of birth control such as oral contraceptives, IUDs or the use of condoms with spermicide.
Competency to give valid informed consent as indicated by a) a Breathalyzer reading at the time the consent form is signed showing an estimated blood alcohol level (BAL) of zero; b) ability to understand the written informed consent form demonstrated by correctly answering questions about the contents of the form after reading the consent form without help (this will also determine whether prospective subjects can read and understand the study questionnaires).
Ability to get to appointments either through personal or public transportation.
Ages 18-65.

Exclusion Criteria:

History of alcohol withdrawal-related seizures, delirium tremens or hallucinations.
Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern (e.g., renal insufficiency, cirrhosis, unstable hypertension, unstable diabetes mellitus, seizure disorder).
History of psychotic disorder or admission for mania, meeting criteria for an eating disorder in the last 2 years, current moderate or severe major depression, current suicidal ideation.
Currently meeting DSM-IV TR criteria for dependence on addictive substances other than alcohol except for nicotine or caffeine. Substance abuse disorders are not exclusionary.
Consumption during the week prior to enrollment or plans to consume during the 12-week trial of benzodiazepines, barbiturates, anticonvulsants or stimulants.
AST or ALT > 5 times ULN, bilirubin > 1.5 X ULN, sodium < 132 or > 150 mMol/L, potassium < 3.2 or > 5.3 mMol/L.
Women who are pregnant or breastfeeding.
Currently participating in or intent to participate in an additional alcohol treatment program during the study period other than Alcoholics Anonymous.
Court-mandated participation in alcohol treatment or pending incarceration.
Intervention: Propofol
Trial phase: Not Applicable
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 82
Group description: Propofol will be administered as the anesthetic maintenance agent.

Propofol: Propofol will be administered.
Eligibility criteria:
Inclusion Criteria:

Patients scheduled for transurethral bladder excision under general anesthesia
ASA I-III

Exclusion Criteria:

Foley catheter less than 18 Fr.
Patients with obstruction of urinary tract
Patients with neurogenic bladder
Patients with severe obesity
Patients with neurologic disorder
Patients with chronic pain
Patients with allergic history to propofol or sevoflurane
Intervention: Sevoflurane
Trial phase: Not Applicable
ATC code: N01AB08
SMILES: FCOC(C(F)(F)F)C(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 82
Group description: Sevoflurane will be administered as the anesthetic maintenance agent.

Sevoflurane: Sevoflurane will be administered.
Eligibility criteria:
Inclusion Criteria:

Patients scheduled for transurethral bladder excision under general anesthesia
ASA I-III

Exclusion Criteria:

Foley catheter less than 18 Fr.
Patients with obstruction of urinary tract
Patients with neurogenic bladder
Patients with severe obesity
Patients with neurologic disorder
Patients with chronic pain
Patients with allergic history to propofol or sevoflurane
Intervention: GABAPENTIN ENACARBIL
Trial phase: Phase 2
SMILES: CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 170
Group description: 600 mg Gabapentin Enacarbil (Horizant)

gabapentin enacarbil: Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
Eligibility criteria:
Inclusion Criteria:

Subjects must meet each one of the following inclusion criteria in order to be eligible for participation in the study:

Be at least 21 years of age.
Have a current (past 12 months) DSM-5 diagnosis of AUD.
Have a BAC by breathalyzer equal to 0.000 when s/he signed the informed consent document (either just prior to or immediately after signing consent).
Be seeking treatment for problems with alcohol.

Additional will be evaluated in clinic.

Exclusion Criteria:

Evaluations will be conducted in clinic.
Intervention: Tranexamic acid
Trial phase: Not Applicable
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 89
Group description: Patients randomized to this arm will receive standard dosing of tranexamic acid intraoperatively.

Tranexamic Acid
Eligibility criteria:
Inclusion Criteria:

Age greater than or equal to 12 years old
Age less than or equal to 45 years old
Indicated for elective periacetabular osteotomy

Exclusion Criteria:

Preoperative use of an anticoagulant (Plavix, warfarin, lovenox, etc.)
History of hypersensitivity to tranexamic acid
History of thromboembolic event (e.g., Pulmonary embolism or Deep vein thrombosis)
History of subarachnoid hemorrhage
History or evidence of hepatic dysfunction (aspartate transaminase-alanine transaminase ratio greater than 60) or renal dysfunction (Creatinine greater than 1.5 mg/dL, or glomerular filtration rate less than 30 mL/minute)
History of seizure
Coronary stents or prior diagnosis of coronary artery disease
Color blindness
Leukemia
Congenital or acquired coagulopathy as evidence by international normalized ratio (INR) greater than 1.4 or partial thromboplastin time (PTT) > 1.4 times normal, or Platelets less than 150,000/mm^3 on preoperative laboratory testing
Use of hormone replacement therapy or hormonal contraceptive agent within 7 days prior to surgery
Pregnant
Breastfeeding
Donated preoperative autologous blood
Younger than 12-years-old and older than 45-years-old
Preoperative hemoglobin less than 10 g/dL
Concomitant open procedures (e.g., femoral osteotomy or osteochondral allograft)
Patients with any contraindication to neuraxial anesthesia:
Patient refusal
History of lumbar spinal fusion
Infection at the site of the epidural
Coagulopathy, as defined above
Ventriculoperitoneal shunt
Intervention: Nitroglycerin
Trial phase: Phase 4
ATC code: C01DA02 | C01DA52 | C05AE01
SMILES: O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)

Nitroglycerin: sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
Eligibility criteria:
Inclusion Criteria:

on coronary angiographic studies, arterial narrowing did not exceed 50% in any of the three main coronary arteries; (
a delayed opacification in at least one of the main coronary arteries was documented. Delayed opacification was defines as corrected TIMI frame count > 23 fps

Exclusion Criteria:

comorbid cardiovascular condition other than mild coronary atherosclerosis and coronary slow flow
refusal to participate
discontinuation of treatment
not returning for the follow up visit